FASEX
Price
$62.09
Change
-$0.07 (-0.11%)
Updated
Jul 31 closing price
Net Assets
373.26M
MVCAX
Price
$34.49
Change
-$0.11 (-0.32%)
Updated
Jul 31 closing price
Net Assets
17.38B
Interact to see
Advertisement

FASEX vs MVCAX

FASEX vs MVCAX Comparison Chart in %
View a ticker or compare two or three
VS
FASEX vs. MVCAX commentary
Aug 03, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is FASEX is a StrongBuy and MVCAX is a Buy.

Interact to see
Advertisement
FUNDAMENTALS
Fundamentals
MVCAX has more cash in the bank: 17.4B vs. FASEX (373M). MVCAX pays higher dividends than FASEX: MVCAX (1.09) vs FASEX (0.90). FASEX was incepted earlier than MVCAX: FASEX (39 years) vs MVCAX (25 years). FASEX (1.20) is less costly to investors than MVCAX (0.98). MVCAX is a more actively managed with annual turnover of: 24.00 vs. FASEX (19.00). FASEX (6%) and MVCAX (6%) have equivalent initial investment costs. MVCAX has a lower initial minimum investment than FASEX: MVCAX (1000) vs FASEX (2500). FASEX annual gain was more profitable for investors over the last year : 12.54 vs. MVCAX (11.71). FASEX return over 5 years is better than : 22.18 vs. MVCAX (17.90).
FASEXMVCAXFASEX / MVCAX
Total Expense Ratio1.130.97116%
Annual Report Gross Expense Ratio1.200.98122%
Fund Existence39 years25 years-
Gain YTD19.42714.699132%
Front Load6%6%100%
Min. Initial Investment25001000250%
Min. Initial Investment IRAN/AN/A-
Net Assets373M17.4B2%
Annual Yield % from dividends0.901.0982%
Returns for 1 year12.5411.71107%
Returns for 3 years23.3019.96117%
Returns for 5 years22.1817.90124%
Returns for 10 years87.2785.46102%
View a ticker or compare two or three
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
RUN9.810.29
+3.05%
Sunrun
FHN25.640.19
+0.75%
First Horizon Corp
MBINM25.670.12
+0.47%
Merchants Bancorp
FSI5.040.01
+0.20%
Flexible Solutions International
KYTX7.30-0.19
-2.54%
Kyverna Therapeutics